(Q47675204)

4 February 2018

title

Fas ligand is not constitutively expressed in low-grade B-cell lymphoma and B-lymphoblastoid cells (English)

1 reference

4 February 2018

1 reference

Carsten Grüllich

1

1 reference

4 February 2018

Manfred Richter

series ordinal

2

1 reference

4 February 2018

Sebastian Exner

series ordinal

3

1 reference

4 February 2018

Jürgen Finke

series ordinal

4

1 reference

4 February 2018

publication date

1 September 2003

1 reference

4 February 2018

European Journal of Haematology

published in

1 reference

4 February 2018

volume

71

1 reference

4 February 2018

issue

3

1 reference

4 February 2018

page(s)

184-188

1 reference

4 February 2018

Apoptotic pathways: the roads to ruin

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

Regulation of the proinflammatory effects of Fas ligand (CD95L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL+ adherent tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

Tumor expression of Fas ligand (CD95L) and the consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

The JAM test. A simple assay for DNA fragmentation and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

7 January 2021

Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

7 January 2021

Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

7 January 2021

Activated B cells express functional Fas ligand

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

7 January 2021

Activation and activation-induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/APO-1) ligand expression and function

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

7 January 2021

Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00117.X

7 January 2021

10.1034/J.1600-0609.2003.00117.X

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018